Our study reveals that tropisetron, a 5-HT3 receptor antagonist, blocks IL-33 expression by inhibiting IRF3 activation and effectively reduces chronic pancreatitis and prevents pancreatic cancer. Here, IRF3 is linked to familial pancreatic carcinoma.